ERBB2 and cholangiocarcinoma: In this phase II study of non‐breast tumor types, HER2‐positivity was detected via gene‐protein assay in 24.3% of patients with UBC, 1.5% with pancreatic cancer, and 8.2% with cholangiocarcinoma.